1220165-92-3 Usage
Description
1-(4-fluorophenyl)-1H-pyrazolo[3,4-c]pyridine-4-carboxylic acid is a chemical compound that belongs to the class of pyrazolo[3,4-c]pyridines. It features a fluorophenyl group and a carboxylic acid functional group, which may contribute to its potential pharmacological applications.
Uses
Used in Pharmaceutical Development:
1-(4-fluorophenyl)-1H-pyrazolo[3,4-c]pyridine-4-carboxylic acid is used as a potential candidate in the development of pharmaceutical drugs for the treatment of certain diseases or conditions. Its unique chemical structure, including the fluorophenyl group and carboxylic acid functional group, may offer specific advantages in drug design and targeting.
Further research and studies are required to fully understand the potential uses and properties of this chemical compound, as its applications in the pharmaceutical industry are still under investigation.
Check Digit Verification of cas no
The CAS Registry Mumber 1220165-92-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,2,0,1,6 and 5 respectively; the second part has 2 digits, 9 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1220165-92:
(9*1)+(8*2)+(7*2)+(6*0)+(5*1)+(4*6)+(3*5)+(2*9)+(1*2)=103
103 % 10 = 3
So 1220165-92-3 is a valid CAS Registry Number.
1220165-92-3Relevant articles and documents
Identification of novel azaindazole CCR1 antagonist clinical candidates
Harcken, Christian,Kuzmich, Daniel,Cook, Brain,Mao, Can,Disalvo, Darren,Razavi, Hossein,Swinamer, Alan,Liu, Pingrong,Zhang, Qiang,Kukulka, Alison,Skow, Donna,Patel, Mita,Patel, Monica,Fletcher, Kimberly,Sherry, Tara,Joseph, David,Smith, Dustin,Canfield, Melissa,Souza, Donald,Bogdanffy, Matthew,Berg, Karen,Brown, Maryanne
, p. 441 - 448 (2019/01/04)
Exploring various cyclization strategies, using a submicromolar pyrazole HTS screening hit 6 as a starting point, a novel indazole based CCR1 antagonist core was discovered. This report presents the design and SAR of CCR1 indazole and azaindazole antagonists leading to the identification of three development compounds, including 19e that was advanced to early clinical trials.
AZAINDAZOLE AMIDE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS
-
, (2011/11/13)
Disclosed are CCR1 inhibitor compounds of the formula (I): which are useful in the treatment of autoimmune and other diseases. Also disclosed a pharmaceutical compositions containing the same, and methods of making and using same.
